SCHEMBL5162427

SCHEMBL5162427

CCc1nc2c(N)nc(SCCc3ccccc3)nc2n1-c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 5/20 0.48
PI4KA P42356 2/20 0.46
PI4K2B Q8TCG2 2/20 0.46
PI4K2A Q9BTU6 2/20 0.46
PI4KB Q9UBF8 2/20 0.46
MAPT P10636 2/20 0.43
NPC1 O15118 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
TLR7 Q9NYK1 2/20 0.40
KDM1A O60341 1/20 0.39
ADORA2A P29274 1/20 0.38
ADORA2B P29275 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5177679 0.94 PI4KA (0.46) ABCB1PI4KAPI4K2BPI4K2API4KB
SCHEMBL5164682 0.91 ABCB1 (0.45) ABCB1PI4KAPI4K2BPI4K2API4KB
SCHEMBL5160802 0.86 MAPT (0.41) ABCB1PI4KAPI4K2BPI4K2API4KB
SCHEMBL5161852 0.78 TLR7 (0.51) PI4KAPI4K2BPI4K2API4KBADORA3
SCHEMBL5161117 0.78 ADORA2A (0.59) PI4KAPI4K2BPI4K2API4KBADORA3
SCHEMBL5163111 0.77 TLR7 (0.53) PI4KAPI4K2BPI4K2API4KBADORA3
SCHEMBL5160564 0.77 ABCB1 (0.51) ABCB1MAPTNPC1CYP1A2CYP2D6
SCHEMBL5163812 0.76 ADORA1 (0.60) PI4KAPI4K2BPI4K2API4KBADORA3
SCHEMBL3441050 0.76 PI4KA (0.49) PI4KAPI4K2BPI4K2API4KBMAPT
SCHEMBL5158659 0.75 ADORA2A (0.53) ABCB1MAPTNPC1CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7189730-B2 A2A adenosine receptor antagonists CV THERAPEUTICS, INC. (US) 2007-03-13 US disclosed
EP-1456209-B1 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS INC (US) 2007-02-28 EP disclosed
US-20030149060-A1 A2A adenosine receptor antagonists CV THERAPEUTICS, INC. 2003-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149060-A1 A2A adenosine receptor antagonists ADORA2A, ADORA2B, ADORA3 ABCB1 1206/4885PI4KA 1091/4885PI4K2B 773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.